Omnicell, Inc. (OMCL)
- Sector
- Health Care
- Last price
- $35.39
- As of
Kresmion compiles this page from OMCL's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
OMNICELL, INC. (OMCL): 7 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-05.
See the full OMCL dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for OMCL on one page. Preview it with sample data, then open it live with a free account.
Preview the OMCL dossierActive signals for OMCL
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 93% of OMCL (2026Q2)
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 95% of OMCL (2026Q2)
- mediumNEW_POSITION
Bridgewater Associates, LP new position in OMCL
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 97.1%, EPS $0.94 vs $0.4769 estimate
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +2144% to OMCL (2026Q1)
FREE, NO ACCOUNT
Every signal on OMCL, as it fires
You are seeing 5 of 13 signals recorded on OMCL since 2026-05-26.
The five above landed across 3 days. The other 8 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in OMCL (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 68213N109 · 2026Q2 | $72M | 0.03% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 68213N109 · 2026Q2 | $33M | 0.02% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 68213N109 · 2026Q2 | $24.8M | 0.03% | , |
| D. E. Shaw & Co., Inc.CUSIP 68213N109 · 2026Q2 | $11.9M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 68213N109 · 2026Q2 | $8.5M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 68213N109 · 2026Q2 | $5.9M | 0.01% | , |
| Bridgewater Associates, LPCUSIP 68213N109 · 2026Q2 | $2.4M | 0.01% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 68213NAF6 · 2026Q2 | $160K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, OMCL
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
OMCL against its peers
OMCL's operating margin of 0.4% ranks in the 52nd percentile of 25 Health Care sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-01-02.
| Metric | OMCL | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.2B USD | 797M USD | 63 | 25 |
| Gross margin | 42.5% | 64.7% | 26 | 16 |
| Operating margin | 0.4% | 0.4% | 52 | 25 |
| Net margin | 0.2% | -0.4% | 56 | 25 |
| Return on equity | 0.2% | -0.3% | 54 | 24 |
| P / E | 884.8x | 40.2x | 95 | 10 |
| 1 year | 19.2% | -5.4% | 65 | 23 |
Peers (25): NVCR, ALHC, ATEC, XRAY, LMAT, AMN, PNTG, CERT, WGS, CNMD, OMDA, INSP, SEM, USPH, PGNY, MD, TNDM, GDRX, PRCT, BKD, IRMD, STAA, TDOC, HSTM, CSTL. Fiscal periods ending between 2025-12-31 and 2026-01-02. Every figure is one full fiscal year read from one annual filing (OMCL: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow OMCL on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to OMCL for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.